Product Name: Aprepitant
Synonyms: 5-[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-
(4-fluorophenyl)morpholin-4-ylmethyl]-3,4-dihydro-2h-1,2,4-triazol-3-
one;aprepitant;5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]
ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,;5-
[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-
fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-
one, Emend;5-[2(R)-[1(R)-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3(S)
-(4-fluorophenyl)morpholin-4-ylmethyl]-3,4-dihydro-2H-1,2,4-triazol-3
-one;5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-
(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3
-one;Emend;MK-0869
CAS: 170729-80-3
MF: C23H21F7N4O3
MW: 534.4266624
Product Categories: Chiral Reagents;Heterocycles;Intermediates & Fine
Chemicals;Pharmaceuticals
mp : 244-246°C
storage temp. : -20°C Freezer
Purity:97%
Package:25kg/drum
Chemical Properties: Off-White to Light Yellow Cyrstalline Solid
Usage: A novel selective neurokinin-1 (NK-1) receptor antagonist. In
vitro studies using human liver microsomes indicate that Aprepitant is
metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and
CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2